AB
Ally Bridge Group
Venture CapitalActiveAlly Bridge Group is a private equity firm specializing in alternative asset classes such as venture capital
37
Investments
5
Exits
$1.5B
AUM
13.5%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Ally Bridge Group.
Investment Thesis & Strategy
Ally Bridge Group invests in various stages of fintech and venture capital companies, seeking alternative asset opportunities.
Investment Activity
Deals per year over the last 5 years
1
20132
20143
20152
20164
2017Portfolio Companies
Selected investments from their portfolio of 37 companies
H
Hansoh Pharmaceutical
Biotech · Growth, 2017
A
Antengene Therapeutics
Biotech · Growth, 2017
H
Harbour BioMed
Biotech · Growth, 2017
Z
Zai Lab
Biotech · Growth, 2017
C
CStone Pharmaceuticals
Biotech · Growth, 2016
I
I-Mab
Biotech · Growth, 2016
I
Innovent Biologics
Biotech · Growth, 2015
G
GenScript Biotech
Biotech · Growth, 2015
C
CanSino Biologics
Biotech · Growth, 2015
B
BeiGene
Biotech · Growth, 2014
L
Legend Biotech
Biotech · Growth, 2014
E
Epizyme
Biotech · Growth, 2013
Notable Exits
CompanyTypeYearValue / Acquirer
WugenAcquisition2024—
CANbridge Life SciencesIPO2021—
Innovent BiologicsIPO2018$3.3B
Zai LabIPO2017$1.04B
GenScript BiotechIPO2015—
Frequently Asked Questions
Ally Bridge Group focuses on Series A, Series B, Series C+ stage investments.